M&A
confidence high
sentiment positive
materiality 0.75
Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox
Cadrenal Therapeutics, Inc.
- Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.
- VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.
- Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.
- HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.
- Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential.